These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 11916549)

  • 1. Concomitant cisplatin and radiotherapy in a conventional and modified fractionation schedule in locally advanced head and neck cancer: a randomised phase II EORTC trial.
    Bartelink H; Van den Bogaert W; Horiot JC; Jager J; van Glabbeke M
    Eur J Cancer; 2002 Mar; 38(5):667-73. PubMed ID: 11916549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
    Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
    Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94).
    Ghadjar P; Simcock M; Studer G; Allal AS; Ozsahin M; Bernier J; Töpfer M; Zimmermann F; Betz M; Glanzmann C; Aebersold DM;
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):524-31. PubMed ID: 21300466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side effects.
    Van den Bogaert W; van der Schueren E; Horiot JC; De Vilhena M; Schraub S; Svoboda V; Arcangeli G; de Pauw M; Van Glabbeke M
    Radiother Oncol; 1995 May; 35(2):91-9. PubMed ID: 7569030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerated bifractionated radiation with concurrent cisplatin administration in locally advanced head and neck cancer: a feasibility study.
    Fountzilas G; Athanassiadis A; Nikolaou A; Kalogera-Fountzila A; Tzitzikas J; Samantas E; Skarlos D; Zamboglou N; Daniilidis J
    Tumori; 1997; 83(4):735-9. PubMed ID: 9349312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II trial, feasibility of combination of daily cisplatinum and accelerated radiotherapy via concomitant boost in stage III non-small cell lung cancer.
    Sarihan S; Darendeliler E; Kizir A; Tuncel N; Oral EN; Karadeniz A; Bilge N
    Lung Cancer; 1998 Apr; 20(1):37-46. PubMed ID: 9699186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant infusion cisplatin and hyperfractionated radiotherapy for locally advanced nasopharyngeal and paranasal sinus tumors.
    Choi KN; Rotman M; Aziz H; Sohn CK; Schulsinger A; Torres C; Har-El G; Chandra P; Bradley T; Rosenthal CJ
    Int J Radiat Oncol Biol Phys; 1997 Nov; 39(4):823-9. PubMed ID: 9369129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
    Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
    Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: results of the EORTC 08912 phase I/II study. European Organization for Research and Treatment of Cancer.
    Uitterhoeve AL; Belderbos JS; Koolen MG; van der Vaart PJ; Rodrigus PT; Benraadt J; Koning CC; González González D; Bartelink H
    Eur J Cancer; 2000 Mar; 36(5):592-600. PubMed ID: 10738123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09.
    Fu KK; Clery M; Ang KK; Byhardt RW; Maor MH; Beitler JJ
    Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):589-97. PubMed ID: 7790243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurotoxicity in a phase I trial of continuous infusion cisplatin with hyperfractionated radiotherapy for locally advanced head and neck cancer.
    Clamon GH; Baatz L; Hoffman HT; Hussey DH; Glascock M; McCulloch TM; Graham SM
    Head Neck; 1996; 18(3):236-41. PubMed ID: 8860764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Combined radiotherapy with cis- or carboplatin in advanced head and neck tumors].
    Zamboglou N; Pape H; Schnabel T; Wurm R; Bannach B; Fürst G; Schmitt G
    Strahlenther Onkol; 1989 Sep; 165(9):647-51. PubMed ID: 2678546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of weekly high-dose cisplatin for six cycles in patients with locally advanced squamous cell carcinoma of the head and neck.
    Planting AS; de Mulder PH; de Graeff A; Verweij J
    Eur J Cancer; 1997 Jan; 33(1):61-5. PubMed ID: 9071901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent chemo-irradiation using accelerated concomitant boost radiation therapy in loco-regionally advanced head and neck squamous cell carcinomas.
    Vivek RS; Baludavid M; Mohanram R; ; ; ; ; ;
    J Cancer Res Ther; 2006; 2(3):90-6. PubMed ID: 17998685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiosensitization by cytotoxic drugs. The EORTC experience by the Radiotherapy and Lung Cancer Cooperative Groups.
    Schaake-Koning C; van den Bogaert W; Dalesio O; Festen J; Hoogenhout J; van Houtte P; Kirkpatrick A; Koolen M; Maat B; Nijs A
    Lung Cancer; 1994 Mar; 10 Suppl 1():S263-70. PubMed ID: 8087519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant boost radiotherapy with concurrent weekly cisplatin in advanced head and neck cancers: a phase II trial.
    Kumar S; Pandey M; Lal P; Rastogi N; Maria Das KJ; Dimri K
    Radiother Oncol; 2005 May; 75(2):186-92. PubMed ID: 16086908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of the treatment outcome of moderately accelerated radiation fractionation (with concurrent chemotherapy in daily dosing) to conventional chemo-radiotherapy in locally advanced head and neck cancers: Supportive in a resource constrained environment.
    Arora C; Sharma N; Kapoor A; Pandya TN
    Indian J Cancer; 2024 Apr; 61(2):262-272. PubMed ID: 38090961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003.
    Fu KK; Pajak TF; Trotti A; Jones CU; Spencer SA; Phillips TL; Garden AS; Ridge JA; Cooper JS; Ang KK
    Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):7-16. PubMed ID: 10924966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14).
    Garden AS; Harris J; Trotti A; Jones CU; Carrascosa L; Cheng JD; Spencer SS; Forastiere A; Weber RS; Ang KK
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1351-5. PubMed ID: 18640496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of adding concomitant chemotherapy to hyperfractionated accelerated radiotherapy for advanced head-and-neck squamous cell carcinoma.
    Nuyts S; Dirix P; Clement PM; Poorten VV; Delaere P; Schoenaers J; Hermans R; Van den Bogaert W
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1088-95. PubMed ID: 18707823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.